Symptomatic intracranial hypertension and prolonged hypocalcemia following treatment of Paget's disease of the skull with zoledronic acid
Carregando...
Citações na Scopus
7
Tipo de produção
article
Data de publicação
2013
Título da Revista
ISSN da Revista
Título do Volume
Editora
SPRINGER JAPAN KK
Citação
JOURNAL OF BONE AND MINERAL METABOLISM, v.31, n.3, p.360-365, 2013
Resumo
Skull involvement in Paget's disease of bone can lead to neurological symptoms, prompting treatment. Intravenous zoledronic acid (ZA) has emerged as an effective and safe treatment option for patients with Paget's, leading to sustained remission and improved quality of life. A previously untreated 61-year-old female presented with 2-year history of facial asymmetry with progressive hearing impairment. Serum calcium levels were normal with upper normal levels of PTH and low 25OHD levels. Serum alkaline phosphatase was markedly increased and bone scan showed extensive pagetic involvement of the skull. Head CT and MRI revealed hydrocephalus with cerebellar tonsillar herniation, platy-basia and basilar invagination. In the absence of clinical signs or symptoms of intracranial hypertension, she was treated with intravenous ZA after 15-day supplementation with calcium and vitamin D. Twelve hours after the infusion, the patient became confused, agitated and disoriented and developed urinary incontinence; cortical sulci became effaced on CT indicating increased intracranial pressure. Over the following days, she developed frank hypocalcemia requiring intravenous calcium infusion and calcitriol. Neurological status returned to normal within 24 h of onset, except for urinary incontinence. Nine months later she remained incontinent and still required calcitriol to maintain normocalcemia. Zoledronic acid is a first-line option for the treatment of Paget's disease, yet there can be complications in particular clinical scenarios such as pagetic hydrocephalus, as seen in this case. Plentiful supplementation of calcium and vitamin D before bisphosphonate therapy is paramount in order to minimize the risk of prolonged post-treatment hypocalcemia.
Palavras-chave
Paget's disease of bone, Pagetic hydrocephalus, Zoledronic acid, Intracranial hypertension, Hypocalcemia
Referências
- Albagha OME, 2011, NAT GENET, V43, P685, DOI 10.1038/ng.845
- Bone HG, 2006, J BONE MINER RES, V21, pP64, DOI 10.1359/JBMR.06S212
- Britton C, 2012, AUST FAM PHYSICIAN, V41, P100
- COOPER C, 2006, J BONE MINER RES S2, V21, P3
- de Castro GRW, 2012, RHEUMATOL INT, V32, P627, DOI 10.1007/s00296-010-1648-2
- Hashimoto J, 2006, J BONE MINER METAB, V24, P186, DOI 10.1007/s00774-005-0670-z
- Kurihara N, 2011, CELL METAB, V13, P23, DOI 10.1016/j.cmet.2010.12.002
- Moiyadi AV, 2006, ACTA NEUROCHIR, V148, P1297, DOI 10.1007/s00701-006-1048-2
- Polyzos SA, 2011, EXP CLIN ENDOCR DIAB, V119, P519, DOI 10.1055/s-0031-1284365
- Polyzos SA, 2010, J BONE MINER METAB, V28, P706, DOI 10.1007/s00774-010-0198-8
- Ralston SH, 2008, LANCET, V372, P155, DOI 10.1016/S0140-6736(08)61035-1
- Reid IR, 2011, J BONE MINER RES, V26, P2261, DOI 10.1002/jbmr.438
- Reis RL, 2011, BR RHEUMATOL INT, DOI [10.1007/s00296-011-2092-7, DOI 10.1007/S00296-011-2092-7]
- Rojas-Villarraga A, 2006, JCR-J CLIN RHEUMATOL, V12, P57, DOI 10.1097/01.rhu.0000208491.78501.71
- Roohi F, 2005, CLIN NEUROL NEUROSUR, V107, P325, DOI 10.1016/j.clineuro.2004.07.007
- Rosen CJ, 2003, NEW ENGL J MED, V348, P1503, DOI 10.1056/NEJM200304103481521
- Rubin DJ, 2009, ENDOCR PRACT, V15, P158
- Singer FR, 2009, NAT REV RHEUMATOL, V5, P483, DOI 10.1038/nrrheum.2009.149
- Siris ES, 2006, J BONE MINER RES, V21, pP94, DOI 10.1359/JBMR.06S218
- Stuckey BGA, 2001, J BONE MINER RES, V16, P1719, DOI 10.1359/jbmr.2001.16.9.1719
- Whitson HE, 2006, BONE, V39, P954, DOI 10.1016/j.bone.2006.04.032